Management of the histologically aggressive non-Hodgkin's lymphomas in adults.
The understanding of lymphocyte biology and lymphomagenesis has increased dramatically in the past two decades, but this has not been matched by rapid advances in therapy. There have been numerous false dawns and these serve to emphasize the importance of large randomized trials. Increasingly, therapy must be designed for specific subgroups of patients, this making it difficult to perform large trials and accentuating the need for multicentre collaboration.